Celgene pays $450m for AZ's MEDI4736 in blood cancers; AZ signs $250m+ Innate deal
This article was originally published in Scrip
Executive Summary
Celgene is paying AstraZeneca $450m up front in order to develop the UK drug maker's anti-PD-L1 product MEDI4736 in a range of blood cancers – a partnership Celgene thinks could be a "meaningful" driver of growth past 2020.
You may also be interested in...
Innate Pursues Anti-Leukemic In EU
Innate Pharma pursues refractory hairy cell leukemia opportunity with first-in-class CD22-directed immunotoxin, moxetumomab pasudotox-tdfk.
Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions
France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.